`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`WOCKHARDT BIO AG,
`TEVA PHARMACEUTICALS USA, INC.,
`AUROBINDO PHARMA U.S.A., INC.,
`SUN PHARMACEUTICAL INDUSTRIES, LTD.,
`SUN PHARMA GLOBAL FZE and
`AMNEAL PHARMACEUTICALS LLC
`Petitioners,
`
`v.
`
`ASTRAZENECA AB,
`Patent Owner.
`
`Case: IPR2015-013401
`U.S. Patent No. RE44,186
`
`
`
` PATENT OWNER’S REQUEST FOR ORAL HEARING
`
`
`
`
`
`
`
`
`
`
`
`1 Petitioner Wockhardt from IPR2016-01029, Petitioner Teva from IPR2016-
`01122, Petitioner Aurobindo from IPR2016-01117, and Petitioners Sun/Amneal
`from IPR2016-01104 have been added as Petitioners to this proceeding.
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.70(a) and the Scheduling Order (Paper No. 17),
`
`Patent Owner AstraZeneca AB respectfully requests oral argument. The
`
`Scheduling Order identified January 25, 2017 for the oral argument; however,
`
`Patent Owner notes that this proceeding is not presently docketed on the PTAB’s
`
`
`
`Public Hearing Schedule.
`
`Patent Owner intends to argue the following issues at the argument:
`
`(1) Any issues raised in Petitioners’ Papers (Nos. 3, 11, 41) or Patent
`
`Owner’s Paper (No. 28) for IPR2015-01340, relating to (a) whether claims 1, 2, 4,
`
`6-11, 25-28, 32-35, 39, and 40, under 35 U.S.C. § 103(a), are obvious over
`
`Ashworth-I (Ex. 1007), Villhauer-1998 (Ex. 1008), Raag (Ex. 1009), and
`
`Hanessian-I (Ex. 1010); (b) whether claims 12-16, 29, 30, 36, 37, 41, and 42, under
`
`35 U.S.C. § 103(a), are obvious over Ashworth-I, Villhauer-1998, Raag,
`
`Hanessian-I, Bachovchin (Ex. 1011), and GLUCOPHAGE Label (Ex. 1012); (c)
`
`whether claims 12, 17, 18, and 22 under 35 U.S.C. § 103(a), are obvious over
`
`Ashworth-I, Villhauer-1998, Raag, Hanessian-I, Bachovchin, and XENICAL
`
`Label (Ex. 1013); (d) whether claims 12, 19, 20, and 21 under 35 U.S.C. § 103(a),
`
`are obvious over Ashworth-I, Villhauer-1998, Raag, Hanessian-I, Bachovchin, and
`
`MEVACOR Label (Ex. 1014); and (e) whether there is evidence of secondary
`
`considerations;
`
`
`
`1
`
`
`
`
`
`
`
`
`(2) Patent Owner’s motions for observation regarding cross-examination of
`
`Petitioners’ reply witnesses and any opposition by Petitioners thereto; and
`
`(3) any issues raised by Petitioners’ in their Request for Oral Hearing.
`
`Because of the technical complexity of the issues in dispute, Patent Owner
`
`requests sixty (60) minutes of time to address these issues. Patent Owner also
`
`requests the ability to use computers at counsel’s table to display demonstrative
`
`exhibits.
`
` Respectfully submitted,
`
`
`
`Dated: December 12, 2016 By: / Anthony A. Hartmann /
` Anthony A. Hartmann, Reg. No. 43,662
` Finnegan, Henderson, Farabow,
` Garrett & Dunner, L.L.P.
` 901 New York Avenue, NW
` Washington DC 20001
` Counsel for Patent Owner
`
`
`
`
`
`
`
`2
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
` The undersigned certifies that copies of the foregoing PATENT OWNER
`
`
`
`
`
`ASTRAZENECA AB’S REQUEST FOR ORAL HEARING was served
`
`electronically via e-mail on December 12, 2016, in its entirety to the following:
`
`Counsel for Petitioner Mylan Pharmaceuticals Inc.:
`
` Steven W. Parmelee
` sparmelee@wsgr.com
`
`
`
` Richard Torczon
` rtorczon@wsgr.com
`
`
`
` Jad A. Mills
` jmills@wsgr.com
`
`
`
` Douglas H. Carsten
` dcarsten@wsgr.com
`
`Counsel for Petitioner Wockhardt BIO AG.:
`
`
`
` Patrick Gallagher
` PCGallagher@duanemorris.com
`
`Counsel for Petitioner Teva Pharmaceuticals U.S.A., Inc..:
`
` Gary Speier
` gspeier@carlsoncaspers.com
`
`
`
` Iain McIntyre
` imcintyre@carlsoncaspers.com
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`Counsel for Petitioner Aurobindo Pharma U.S.A., Inc..:
`
`
`
` Sailesh K. Patel
` SPatel@schiffhardin.com
`
`
`
` George Yu
` GYu@schiffhardin.com
`
`Counsel for Petitioners Sun/Amneal:
`
`
`
` Samuel Park
` SPark@winston.com
`
`
`
` Andrew Sommer
` ASommer@winston.com
`
`
`
`Dated: December 12, 2016 By: /Lauren K. Young/
` Lauren K. Young
` Litigation Legal Assistant
` FINNEGAN, HENDERSON, FARABOW,
` GARRETT & DUNNER, L.L.P.
`
`
`
`
`
`
`
`
`4